Datapoint: Sarepta Scores Label Expansion for Elevidys

The FDA last week expanded the label for Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl) to include all Duchenne muscular dystrophy (DMD) patients aged 4 and older. The drug — the first gene therapy available to treat DMD — received accelerated approval in 2023, but was only available to ambulatory male patients aged 4 to 5. “The initial approval of ELEVIDYS was a significant milestone, and the expanded indication means clinicians now have a treatment option for the great majority of boys and young men living with Duchenne,” Dr. Jerry Mendell, the co-inventor of Elevidys and senior advisor, medical affairs at Sarepta said in a statement. Elevidys, which is administered as a one-time intravenous infusion, currently holds covered or better status for 47% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/24/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 18

Datapoint: Arcutis Scores New Indication for Zoryve

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 17

Datapoint: Blue Shield of California Adds New Weight Loss, Diabetes Programs to Digital Health Platform

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 16

Datapoint: Sanford, Marshfield Clinic to Merge

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today